Once-monthly risedronate for postmenopausal osteoporosis

Area of Science:

• Pharmacology
• Bone Metabolism
• Geriatric Medicine

Background:

• Bisphosphonates are primary treatments for postmenopausal osteoporosis.
• Low patient adherence to bisphosphonate therapy is a significant clinical problem, leading to increased fracture risk.
• Understanding factors influencing adherence is crucial for effective osteoporosis management.

Purpose of the Study:

• To review the physicochemical properties of bisphosphonates that enable intermittent dosing.
• To assess whether less frequent dosing regimens improve patient compliance and persistence.
• To compare the safety and efficacy of various bisphosphonate formulations, including oral and intravenous options.

Main Methods:

• Literature review of clinical trials and pharmacological data on bisphosphonates.
• Comparative analysis of different dosing frequencies (daily, weekly, monthly oral; quarterly, annual IV).
• Emphasis on the efficacy and safety profile of once-monthly oral risedronate.

Main Results:

• Bisphosphonates offer various dosing schedules, from daily to annual administration.
• Once-monthly oral risedronate demonstrates efficacy in reducing vertebral and non-vertebral fractures.
• Risedronate is the first monthly oral bisphosphonate with proven reduction in both vertebral and non-vertebral fractures.

Conclusions:

• Convenient dosing regimens for bisphosphonates may improve adherence in osteoporosis patients.
• The long-term impact of monthly oral bisphosphonates like risedronate on compliance and fracture reduction requires further investigation.
• Optimizing bisphosphonate therapy adherence is essential for mitigating fracture risk in postmenopausal women.